An inhibitor of SUR1/Kir6.2, SUR2A/Kir6.2, and SUR2B/Kir6.2
Related Products
Active Metabolite(s)
34278trans-hydroxy Glimepiride
Labeled Version(s)
27846Glimepiride-d4
Metabolite(s)
34277trans-carboxy Glimepiride
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Glimepiride

Item No. 12090

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide
CAS Number
93479-97-1
Synonyms
  • HOE 490
Molecular Formula
C24H34N4O5S
Formula Weight
490.6
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 3 mg/ml
λmax
228 nm
SMILES
O=S(C1=CC=C(CCNC(N2C(C(CC)=C(C)C2)=O)=O)C=C1)(NC(N[C@H]3CC[C@H](C)CC3)=O)=O
InChi Code
InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-
InChi Key
WIGIZIANZCJQQY-RUCARUNLSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 mg

    $54

    Add

    1 g

    $75

    Add

    5 g

    $262

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Glimepiride is an inhibitor of sulfonylurea receptors (SURs) linked to the inwardly rectifying potassium channel (Kir6.2; IC50s = 3, 5.4, and 7.3 nM for SUR1/Kir6.2, SUR2A/Kir6.2, and SUR2B/Kir6.2, respectively, in Xenopus oocytes expressing the mouse receptor).1 It also induces intracellular insulin receptor (InsR) complex dissociation and insulin degradation in HepG2 cells when used at a concentration of 20 µM.2 Glimepiride (0.05 mg/kg per day) decreases blood glucose and plasma insulin levels in a KKAy mouse model of insulin-resistant type 2 diabetes.3 It reduces hemoglobin A1c (HbA1c) levels in the same model when administered at a dose of 0.5 mg/kg per day. Formulations containing glimepiride have been used in the treatment of type 2 diabetes mellitus.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Song, D.K., and Ashcroft, F.M. Glimepiride block of cloned β-cell, cardiac and smooth muscle KATP channels. Br. J. Pharmacol. 133(1), 193-199 (2001).

    2. Hribal, M.L., D'Alfonso, R., Giovannone, B., et al. The sulfonylurea glimepiride regulates intracellular routing of the insulin-receptor complexes through their interaction with specific protein kinase C isoforms. Mol. Pharmacol. 59(2), 322-330 (2001).

    3. Müller, G., Satoh, Y., and Geisen, K. Extrapancreatic effects of sulfonylureas - a comparison between glimepiride and conventional sulfonylureas. Diabetes Res. Clin. Pract. 28(Suppl 1), S115-S137 (1995).